Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
Recent CRBU News
- Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/27/2026 08:05:00 PM
- Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2026 08:05:00 PM
- Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting • GlobeNewswire Inc. • 05/12/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:10:46 PM
- Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/07/2026 08:05:00 PM
- Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference • GlobeNewswire Inc. • 05/05/2026 08:05:00 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/01/2026 08:03:01 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:03:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:01:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:01:34 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/10/2026 08:01:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:02:47 PM
- Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2026 10:11:55 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 09:09:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 09:07:40 PM
- Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/05/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:01:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 02:42:17 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/25/2026 10:16:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 01:54:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 01:54:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 01:53:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 10:28:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 10:28:13 PM
